These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Quest to improve marrow transplant success yields new approaches to graft-vs-host disease. Kirn TF JAMA; 1987 Sep; 258(11):1438-9. PubMed ID: 3306001 [No Abstract] [Full Text] [Related]
23. Treatment with apremilast was beneficial for chronic graft-versus-host disease skin lesion in a patient with psoriasis. Ichiyama S; Komatsu T; Hoashi T; Kanda N; Nagai K; Yamada Y; Ansai SI; Saeki H J Dermatol; 2019 Jun; 46(6):e218-e219. PubMed ID: 30632183 [No Abstract] [Full Text] [Related]
24. Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model. Vogelsang GB; Wells MC; Santos GW; Chen TL; Hess AD Transplant Proc; 1988 Apr; 20(2 Suppl 2):226-8. PubMed ID: 3284069 [No Abstract] [Full Text] [Related]
25. Thalidomide responsive chronic pulmonary GVHD. Forsyth CJ; Cremer PD; Torzillo P; Iland HJ; Young GA Bone Marrow Transplant; 1996 Feb; 17(2):291-3. PubMed ID: 8640183 [TBL] [Abstract][Full Text] [Related]
26. The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information. Wood PM; Proctor SJ Leuk Res; 1990; 14(5):395-9. PubMed ID: 2189044 [TBL] [Abstract][Full Text] [Related]
27. Thalidomide--the need for a new clinical evaluation of an old drug. Ehninger G; Eger K; Stuhler A; Schuler U Bone Marrow Transplant; 1993; 12 Suppl 3():S26-8. PubMed ID: 8124253 [TBL] [Abstract][Full Text] [Related]
28. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281 [TBL] [Abstract][Full Text] [Related]
29. Thalidomide in chronic graft-versus-host disease after stem cell transplantation: effects on quality of life. Miller S; Sharda S; Rodrigue J; Mehta P Int J Hematol; 2002 Nov; 76(4):365-9. PubMed ID: 12463602 [TBL] [Abstract][Full Text] [Related]
30. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NK; Wagner J; Enright H Bone Marrow Transplant; 2000 Oct; 26(8):865-9. PubMed ID: 11081386 [TBL] [Abstract][Full Text] [Related]
31. Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases. Tolland JP; Devereux C; Jones FC; Bingham EA Pediatr Dermatol; 2008; 25(2):240-4. PubMed ID: 18429789 [TBL] [Abstract][Full Text] [Related]
32. [Thalidomide once more in the spotlight]. de Jong-van den Berg LT; Rutgers J; Cornel MC Ned Tijdschr Geneeskd; 1998 Nov; 142(46):2509-12. PubMed ID: 10028338 [TBL] [Abstract][Full Text] [Related]
33. Thalidomide for chronic graft-versus-host disease in children. Heney D; Lewis IJ; Bailey CC Lancet; 1988 Dec; 2(8623):1317. PubMed ID: 2904042 [No Abstract] [Full Text] [Related]
34. Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease. Flowers ME; Martin PJ Leuk Lymphoma; 2003 Jul; 44(7):1141-6. PubMed ID: 12916865 [TBL] [Abstract][Full Text] [Related]
35. Graft-versus-host disease. Kaitin KI N Engl J Med; 1991 Aug; 325(5):357-8. PubMed ID: 2057040 [No Abstract] [Full Text] [Related]
36. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM Bone Marrow Transplant; 2001 Dec; 28(12):1145-50. PubMed ID: 11803357 [TBL] [Abstract][Full Text] [Related]